Brain injury is one of the most heavily marketed off-label uses of HBOT. Veterans, athletes, and concussion survivors see ads daily. The trial record behind those ads is much weaker than the marketing suggests.
This page lays out what the rigorous trials actually show. The short version up front: the best-designed studies have largely failed to find a benefit over sham.
Quick Facts
| Field | Value |
|---|---|
| FDA approval status | NOT approved for brain injury |
| UHMS classification | Not on the 14 approved indications list |
| Medicare coverage | NOT covered for brain injury |
| TRICARE / VA coverage | Generally not covered; VA still researching |
| Typical out-of-pocket | $6,000-$15,000 for a 40-session course |
| Evidence grade | Low — best-designed RCTs are negative |
The evidence
Brain injury HBOT has a deep trial record. The story it tells is sobering. Rigorous designs keep failing.
The Wolf and colleagues 2012 Journal of Neurotrauma trial, PMID 22455496 ran a sham-controlled study in 50 service members with combat-related concussion symptoms. The HBOT arm and the sham arm both improved. There was no statistical edge for the active treatment.
The Cifu and colleagues 2014 Annals of Neurology trial, PMID 24255008 was larger and tighter. Sixty-one Marines were randomized to sham, 1.5 ATA, or 2.0 ATA. By three months, no arm beat sham on any functional, cognitive, or psychomotor measure.
That trial is the most rigorous data we have. It is firmly negative.
The Harch and colleagues 2020 Medical Gas Research trial, PMID 32189664 was positive. Fifty-six civilians and veterans showed improvements on symptom and cognition measures versus controls. The control arm was wait-list, not sham, which weakens the comparison.
A 2017 Harch case-control paper in Medical Gas Research, PMID 29152209 reported gains in symptoms and SPECT imaging in 30 military subjects. No sham group was used.
The Boussi-Gross 2013 PLoS ONE trial, PMID 24260334 used a crossover design with delayed-treatment controls. The Israeli group reported gains. The crossover design and lack of true sham left it open to the same objections.
The Hart and colleagues 2019 multicenter study, PMC 6463441 was observational across multiple US sites. It pooled outcomes but lacked randomization.
A 2017 PMC review of HBOT for brain injury, PMC 5426690 summarized the overall picture. The conclusion was that the rigorous sham-controlled trials had not shown benefit, while open-label work showed gains likely driven by placebo and study design.
The Tsutsumi Cochrane protocol on HBOT for post-concussion syndrome, 2017 was registered to address this gap. The pattern across formal evidence reviews is consistent — uncertain benefit, methodology problems, and need for better trials.
The pattern is clear. When you place the rigorous sham-controlled trials next to the open-label and wait-list studies, the rigorous ones fail.
Why people pursue this anyway
Concussion recovery is hard. Standard care plateaus and symptoms can drag on for months or years. The promise of more healing is emotionally powerful.
A clinic chain pushed for global marketing around the Israeli protocols. Other wellness brands such as Restore Hyper Wellness and clinics led by Paul Harch market HBOT for concussion. Veterans groups have lobbied Congress to cover the treatment.
Independent operators using chambers from OxyHealth, Sechrist Industries, Perry Baromedical, Summit to Sea, ETC Biomedical, and Healing Chambers International round out the long tail.
The honest gap is that veteran testimonials and one positive Israeli trial do not match what controlled trials show. Patients deserve to know that gap before they pay.
For deeper context on the marketing-vs-evidence split, see our evidence-vs-marketing review of this clinic chain and our analysis of institutional silence on HBOT. For related framing on performance claims see our athletic recovery analysis.
What clinical guidelines say
The US Department of Defense and Department of Veterans Affairs clinical practice guideline for concussion does not recommend HBOT. The VA has funded several trials and continues to research the question.
The American Academy of Neurology does not list HBOT as a recommended therapy for chronic concussion symptoms. Major academic neurology centers do not offer it for this use.
UHMS does not include brain injury on its 14 approved indications list. The official UHMS HBO indications page, 2024 is the source of truth.
The silence from these bodies is not an oversight. It reflects the trial record. Two large negative RCTs in service members carry more weight than open-label gains.
Cost versus evidence
A 40-session course at a wellness clinic runs $6,000 to $15,000. Premium chain packages can run higher.
Veterans face this cost without TRICARE or VA support outside of research protocols. HSA and FSA accounts may or may not accept the claim.
That price stacks against two large sham-controlled negative trials. The math asks a hard question — does it justify a five-figure spend on an investigational protocol?
The framing is not that no patient should try this. The framing is that the trial record does not match the marketing.
What to ask your physician
Patients considering HBOT for brain injury can ask several questions. Each cuts through the marketing.
What is the FDA status for this use — the answer is "not approved." How did the Wolf 2012 and Cifu 2014 trials turn out — the answer is "negative." What does my neurologist think of the evidence — the answer varies but is usually cautious.
For chamber-type details, see our hard-shell vs soft-shell chamber explainer. The Harch and Israeli protocols use medical-grade hard chambers from makers such as Sechrist Industries and Perry Baromedical, not the soft chambers from OxyHealth and Summit to Sea found at most wellness centers.
Distinguishing from FDA-approved uses
Brain injury sits very differently from approved HBOT uses. The approved list — carbon monoxide poisoning, dive injury, stubborn bone infection, diabetic foot wounds, and ten others — all have decades of backing data.
Our carbon monoxide poisoning evidence atlas and decompression sickness evidence atlas show what real FDA-approved HBOT evidence looks like — multiple independent trials, multi-center designs, and a settled mechanism.
Brain injury does not have that backing. The honest call is to label it "investigational" and let patients decide with open eyes.
Frequently asked questions
Is HBOT FDA-approved for brain injury?
No. The FDA recognizes 14 conditions for HBOT and brain injury is not among them. The UHMS approved indications list, current 2024, also does not include brain injury or concussion symptoms.
What did the major sham-controlled trials show?
Wolf 2012 and Cifu 2014 both compared HBOT to sham compression in service members. Neither found a benefit for the active treatment at three months. The Cifu paper is the most rigorous design in the literature and was firmly negative.
Will TRICARE, the VA, or Medicare cover this?
Generally no. Medicare and most commercial plans cover HBOT only for the 14 approved indications. The VA has funded research but does not cover routine off-label HBOT for concussion. Most veterans pay out of pocket.
How much does a course cost?
Most wellness clinics charge $250 to $400 per session. A 40-session course runs $6,000 to $15,000. Premium chain packages are often higher.
Why do some patients say it helped?
Open-label trials, wait-list controls, and case series consistently show gains. Sham-controlled designs do not. The gap suggests that placebo effects, regression to the mean, and study design account for much of the perceived benefit.
Sources
- Wolf and colleagues 2012, PMID 22455496
- Cifu and colleagues 2014, PMID 24255008
- Harch and colleagues 2020, PMID 32189664
- Harch case-control 2017, PMID 29152209
- Boussi-Gross 2013, PMID 24260334
- Hart multicenter 2019, PMC 6463441
- PMC 2017 rapid evidence review
- Tsutsumi Cochrane protocol 2017
- UHMS HBO Indications List, 2024
Medical disclaimer
This page is medical journalism and not medical advice. HBOT for brain injury is an investigational off-label use without FDA approval. Standard concussion care including cognitive rest, graded return to activity, and clinical follow-up remains the guideline-recommended path. Talk to your neurologist before pursuing any out-of-pocket HBOT protocol. This page does not diagnose or substitute for professional medical care.